Biomerica applies for a PLA code to enhance patient access to its inFoods IBS diagnostic test for personalized IBS management. Biomerica, Inc. has submitted an application to the American Medical ...
These results exemplify how PLA repeat testing of lesions that may have evolved over time after the initial negative PLA test, can identify early-stage melanoma and benefit patients. “These results ...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc., a molecular genomics company pioneering precision dermatology, announces the publication of a new clinical study, confirming the clinical utility of ...
IRVINE, Calif. , May 07, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company dedicated to the development of advanced diagnostic products, announced that the Company ...
LA JOLLA, Calif.--(BUSINESS WIRE)-- DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the topline results ...
The inFoods ® IBS test is a novel, non-invasive diagnostic that identifies patient-specific IBS trigger foods that may be contributing to IBS symptoms such as bloating, abdominal pain, diarrhea, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback